文献速递母胎医学产科

后TOTAL试验时代先天性膈疝胎儿手术应如何实施:一场讨论

How should fetal surgery for congenital diaphragmatic hernia be implemented in the post-TOTAL trial era: A discussion.
PubMed 文献 · Prenat Diagn · 2022-01-22

本文讨论TOTAL试验后先天性膈疝胎儿手术的实施。两项随机对照试验显示,重度病例在27+0至29+6周行胎儿镜下气管内球囊封堵术(FETO)使存活出院率提高25%(95%CI +6至+46;p=0.0091),中度病例在30+0至31+6周行FETO提高13%(95%CI -1至+28;p=0.059)。讨论者指出观察到的存活率低于部分高容量中心报告,并关注早产远期影响、低容量中心纳入及严重医源性并发症风险,认为结果可能不可推广。

要点

  • 重度先天性膈疝(对侧肺<25%)在27+0至29+6周行FETO,存活出院率提高25%(95%CI +6至+46;p=0.0091)。
  • 中度先天性膈疝(对侧肺25%-45%)在30+0至31+6周行FETO,存活出院率提高13%(95%CI -1至+28;p=0.059)。
  • 讨论者认为FETO仍有早产高风险,球囊无法取出时可致死,结果可能不可推广。

核心结论

  • 讨论者认为FETO可能有一定价值,但仍是有早产高风险的操作,且当球囊无法在分娩前取出时可致死。

研究设计与样本

  • 本文为对TOTAL试验的讨论,讨论者包括试验负责人(JD)和未参与试验的同事(AF)。
  • TOTAL试验为两项随机对照试验,比较孤立性先天性膈疝胎儿的FETO与期待管理的结局,注册号为NCT01240057(重度)和NCT00763737(中度)。

主要发现

  • 重度病例在27+0至29+6周行FETO,存活出院率提高25%(95%CI +6至+46;p=0.0091)。
  • 中度病例在30+0至31+6周行FETO,存活出院率提高13%(95%CI -1至+28;p=0.059)。
  • 早期FETO后分娩孕周平均提前3.2周(95%CI 2.3至4.1周),晚期FETO后平均提前1.7周(95%CI 1.1至2.3周)。

关键数值与推荐

  • 重度肺发育不良定义为超声中对侧肺大小<25%。
  • 中度肺发育不良定义为超声中对侧肺大小为正常的25%至45%。
  • 重度病例FETO在27+0至29+6周(早期)进行,中度病例在30+0至31+6周(晚期)进行。

临床怎么用

  • 对于预测出生后结局差的胎儿,可考虑逆转肺发育不良的操作。
  • 讨论者指出观察到的存活率(治疗和期待管理胎儿)总体低于部分高容量中心(尤其北美)报告的水平。
  • 讨论者认为结果可能不可推广。

局限性

  • 讨论者指出观察到的存活率(治疗和期待管理胎儿)总体低于部分高容量中心(尤其北美)报告的水平。
  • 讨论者指出早产对远期的潜在影响。
  • 讨论者指出纳入了低容量中心。
  • 讨论者指出FETO可能导致严重医源性并发症。
  • 讨论者认为结果可能不可推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Following prenatal diagnosis of congenital diaphragmatic hernia, severity can be predicted based on the presence of associated abnormalities, and in isolated cases, on lung size and position of the liver. Severe hypoplasia is defined by a contralateral lung size <25% on ultrasound; moderate hypoplasia is when that lung measures between 25% and 45% of the normal. In fetuses with predicted poor postnatal outcome a procedure that reverses pulmonary hypoplasia may be considered. In uncontrolled studies, fetoscopic endoluminal tracheal occlusion (FETO) improved neonatal outcome. Recently, two randomized controlled trials compared the neonatal and infant outcomes in fetuses with isolated CDH (www.totaltrial.eu). In severe cases, FETO was carried out at 27+0 -29+6 weeks' gestation (referred to as "early") and in moderate at 30+0 -31+6 weeks ("late"). Survival to discharge from the neonatal intensive care unit increased by 25% (95%-CI:+6 to +46; p = 0.0091) and 13% (-1 to +28; p = 0.059), in fetuses with severe and moderate cases, respectively. Following FETO gestational age at delivery was on average 3.2 (2.3-4.1) weeks earlier following early and 1.7 (1.1-2.3) following late FETO. Here the strengths and weaknesses of the TOTAL trials and their translation to the clinic are debated. Discussants are the lead for the trial (JD) and a colleague (AF) not involved. The discussant notes that the observed survival, both in treated and expectantly managed fetuses, was overall less than what is reported by some high volume centers, particularly in North America. Additional criticisms are the potential effects of prematurity on the long term, the inclusion of low-volume centers, and the potential of FETO for severe iatrogenic complications. Therefore results may not be generalizable. The discussants concluded that although FETO may have its value it remains a procedure with a high risk for prematurity and it can be lethal when the balloon cannot be removed prior to delivery. CLINICAL TRIAL REGISTRATION: The TOTAL trials were registered at www.clinicaltrials.gov as NCT01240057 (severe) and NCT00763737 (moderate).

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Deprest J, Flake A. How should fetal surgery for congenital diaphragmatic hernia be implemented in the post-TOTAL trial era: A discussion. Prenat Diagn. 2022. PMID: 35032132. doi:10.1002/pd.6091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。